Knowledge-map analysis of bladder cancer immunotherapy

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–12. doi:10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• Ritch CR, Velasquez MC, Kwon D, Becerra MF, Soodana-Prakash N, Atluri VS, Almengo K, Alameddine M, Kineish O, Kava BR, et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol. 2020 Mar;203(3):505–11. doi:10.1097/JU.0000000000000593.
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017 Mar;71(3):462–75. doi:10.1016/j.eururo.2016.06.020.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol. 2021 Apr 16;12:672356. doi:10.3389/fimmu.2021.672356.
   PubMed Web of Science ®Google Scholar
• Vasekar M, Degraff D, Joshi M. Immunotherapy in bladder cancer. Curr Mol Pharmacol. 2016;9(3):242–51. doi:10.2174/1874467208666150716120945.
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol. 2014 Mar;11(3):153–62. doi:10.1038/nrurol.2014.15.
   PubMed Web of Science ®Google Scholar
• Wołącewicz M, Hrynkiewicz R, Grywalska E, Suchojad T, Leksowski T, Roliński J, Niedźwiedzka-Rystwej P. Immunotherapy in bladder cancer: current methods and future perspectives. Cancers Basel. 2020 May 7;12(5):1181. doi:10.3390/cancers12051181.
   PubMed Web of Science ®Google Scholar
• Wu Z, Liu J, Dai R, Wu S. Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci. 2021 Apr;64(4):512–33. doi:10.1007/s11427-020-1768-y.
   PubMed Web of Science ®Google Scholar
• Tulsi R, Haque MMU, Hanif FM, Devi A, Mubarak M, Hassan Luck N. Metastasis of duodenal adenocarcinoma to the urinary bladder presenting as hematuria. J Transl Int Med. 2021 Jan 29;9(2):143–5. doi:10.2478/jtim-2021-0010.
   PubMed Web of Science ®Google Scholar
• Wallin JA. Bibliometric methods: pitfalls and possibilities. Basic Clin Pharmacol Toxicol. 2005 Nov;97(5):261–75. doi:10.1111/j.1742-7843.2005.pto_139.x.
   PubMed Web of Science ®Google Scholar
• Guler AT, Waaijer CJ, Palmblad M. Scientific workflows for bibliometrics. Scientometrics. 2016;107(2):385–98. doi:10.1007/s11192-016-1885-6.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng S-L, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27;515(7528):558–62. doi:10.1038/nature13904.
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013 Mar;63(3):462–72. doi:10.1016/j.eururo.2012.10.039.
   PubMed Web of Science ®Google Scholar
• Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021 Jul;22(7):919–30. doi:10.1016/S1470-2045(21)00147-9.
   PubMed Web of Science ®Google Scholar
• Hu B, Wang Z, Zeng H, Qi Y, Chen Y, Wang T, Wang J, Chang Y, Bai Q, Xia Y, et al. Blockade of DC-SIGN+ tumor-associated macrophages reactivates antitumor immunity and improves immunotherapy in muscle-invasive bladder cancer. Cancer Res. 2020 Apr 15;80(8):1707–19. doi:10.1158/0008-5472.CAN-19-2254.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou Q, Wang Z, Zhang H, Zeng H, Huang Q, Chen Y, Jiang W, Lin Z, Qu Y, et al. Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. J Immunother Cancer. 2020 Aug;8(2):e000978. doi:10.1136/jitc-2020-000978.
   PubMed Web of Science ®Google Scholar
• Hu J, Chen J, Ou Z, Chen H, Liu Z, Chen M, Zhang R, Yu A, Cao R, Zhang E, et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study. Cell Rep Med. 2022 Nov 15;3(11):100785. doi:10.1016/j.xcrm.2022.100785.
   PubMedGoogle Scholar
• Whang YM, Yoon DH, Hwang GY, Yoon H, Park SI, Choi YW, Chang IH. Liposome-encapsulated Bacillus Calmette–Guérin cell wall skeleton enhances antitumor efficiency for bladder cancer in vitro and in vivo via induction of AMP-Activated Protein Kinase. Cancers Basel. 2020 Dec 8;12(12):3679. doi:10.3390/cancers12123679.
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976 Aug;116(2):180–3. doi:10.1016/S0022-5347(17)58737-6.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909–20. doi:10.1016/S0140-6736(16)00561-4.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest oncology group study. J Urol. 2000 Apr;163(4):1124–9. doi:10.1016/S0022-5347(05)67707-5.
   PubMed Web of Science ®Google Scholar
• Bandini M, Gibb EA, Gallina A, Raggi D, Marandino L, Bianchi M, Ross JS, Colecchia M, Gandaglia G, Fossati N, et al. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆. Ann Oncol. 2020 Dec;31(12):1755–63. doi:10.1016/j.annonc.2020.09.011.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002 Nov;168(5):1964–70. doi:10.1016/S0022-5347(05)64273-5.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm M-O, Bracarda S, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312–22. doi:10.1016/S1470-2045(17)30065-7.
   PubMed Web of Science ®Google Scholar
• Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15;16(10):2861–71. doi:10.1158/1078-0432.CCR-10-0569.
   PubMed Web of Science ®Google Scholar
• Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019 Nov;25(11):1706–14. doi:10.1038/s41591-019-0628-7.
   PubMed Web of Science ®Google Scholar
• Szabados B, Kockx M, Assaf ZJ, van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022 Aug;82(2):212–22. doi:10.1016/j.eururo.2022.04.013.
   PubMed Web of Science ®Google Scholar
• Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018 Dec 1;36(34):3353–60. doi:10.1200/JCO.18.01148.
   PubMed Web of Science ®Google Scholar
• van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, van Montfoort ML, van Rooijen C, Peters D, Broeks A, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020 Dec;26(12):1839–44. doi:10.1038/s41591-020-1085-z.
   PubMed Web of Science ®Google Scholar
• Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 Dec;26(12):1845–51. doi:10.1038/s41591-020-1086-y.
   PubMed Web of Science ®Google Scholar
• Sfakianos JP, Salome B, Daza J, Farkas A, Bhardwaj N, Horowitz A. Bacillus Calmette-Guerin (BCG): its fight against pathogens and cancer. Urol Oncol. 2021 Feb;39(2):121–9. doi:10.1016/j.urolonc.2020.09.031.
   PubMed Web of Science ®Google Scholar
• Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006 Jun;67(6):1216–23. doi:10.1016/j.urology.2005.12.014.
   PubMed Web of Science ®Google Scholar
• Buffen K, Oosting M, Quintin J, Ng A, Kleinnijenhuis J, Kumar V, van de Vosse E, Wijmenga C, van Crevel R, Oosterwijk E, et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 2014 Oct 30;10(10):e1004485. doi:10.1371/journal.ppat.1004485.
   PubMed Web of Science ®Google Scholar
• Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, et al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014 Oct;66(4):677–88. doi:10.1016/j.eururo.2014.02.061.
   PubMed Web of Science ®Google Scholar
• Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Tejido Á, San Juan R, Arrebola-Pajares A, Lizasoain M, Prieto S, Aguado JM. Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Med. 2014 Oct;93(17):236–54. doi:10.1097/MD.0000000000000119.
   PubMed Web of Science ®Google Scholar
• Lam JS, Benson MC, O’Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH, Sawczuk IS. Bacillus Calmette-Guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol. 2003 Sep-Oct;21(5):354–60. doi:10.1016/S1078-1439(03)00012-7.
   PubMed Web of Science ®Google Scholar
• Bunimovich-Mendrazitsky S, Halachmi S, Kronik N. Improving bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model. Math Med Biol. 2016 Jun;33(2):159–88. doi:10.1093/imammb/dqv007.
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021 Jun 3;384(22):2102–14. doi:10.1056/NEJMoa2034442.
   PubMed Web of Science ®Google Scholar
• Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020 Sep;70(5):404–23. doi:10.3322/caac.21631.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67–76. doi:10.1016/S0140-6736(16)32455-2.
   PubMed Web of Science ®Google Scholar
• Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018 Feb 24;391(10122):748–57. doi:10.1016/S0140-6736(17)33297-X.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. KEYNOTE-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015–26. doi:10.1056/NEJMoa1613683.
   PubMed Web of Science ®Google Scholar
• Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483–92. doi:10.1016/S1470-2045(17)30616-2.
   PubMed Web of Science ®Google Scholar
• Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, et al. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021 Jan 1;11(7):3089–108. doi:10.7150/thno.53649.
   PubMed Web of Science ®Google Scholar
• Burke B, Eden C, Perez C, Belshoff A, Hart S, Plaza-Rojas L, Delos Reyes M, Prajapati K, Voelkel-Johnson C, Henry E, et al. Inhibition of histone deacetylase (HDAC) enhances checkpoint blockade efficacy by rendering bladder cancer cells visible for T cell-mediated destruction. Front Oncol. 2020 May 15;10:699. doi:10.3389/fonc.2020.00699.
   PubMed Web of Science ®Google Scholar
• Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, Thelemaque C, Lebacle C, Thibault C, Audenet F, et al. Escherichia coli –specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov. 2022 Oct 5;12(10):2280–307. doi:10.1158/2159-8290.CD-22-0201.
   PubMed Web of Science ®Google Scholar
• Nikolos F, Hayashi K, Hoi XP, Alonzo ME, Mo Q, Kasabyan A, Furuya H, Trepel J, Di Vizio D, Guarnerio J, et al. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nat Commun. 2022 Mar 28;13(1):1487. doi:10.1038/s41467-022-29026-9.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Ma AH, Zhang H, Lin T-Y, Xue X, Farrukh H, Zhu S, Shi W, Yuan R, Cao Z, et al. Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer. Clin Cancer Res. 2022 Nov 1;28(21):4820–31. doi:10.1158/1078-0432.CCR-22-1362.
   PubMed Web of Science ®Google Scholar
• Zhu S, Ma AH, Zhu Z, Adib E, Rao T, Li N, Ni K, Chittepu VCSR, Prabhala R, Garisto Risco J, et al. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. J Immunother Cancer. 2021 Nov;9(11):e002917. doi:10.1136/jitc-2021-002917.
   PubMed Web of Science ®Google Scholar
• Ji N, Mukherjee N, Reyes RM, Gelfond J, Javors M, Meeks JJ, McConkey DJ, Shu Z-J, Ramamurthy C, Dennett R, et al. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J Immunother Cancer. 2021 Mar;9(3):e001941. doi:10.1136/jitc-2020-001941.
   PubMed Web of Science ®Google Scholar
• Li H, Chen J, Li Z, Chen M, Ou Z, Mo M, Wang R, Tong S, Liu P, Cai Z, et al. S100A5 attenuates efficiency of anti-PD-L1/PD-1 immunotherapy by inhibiting CD8+ T cell-mediated anti-cancer immunity in bladder carcinoma. Adv Sci. 2023 Sep;10(25):e2300110. doi:10.1002/advs.202300110.
   Web of Science ®Google Scholar
• Cai Z, Chen J, Yu Z, Li H, Liu Z, Deng D, Liu J, Chen C, Zhang C, Ou Z, et al. BCAT2 shapes a noninflamed tumor microenvironment and induces resistance to anti-PD-1/PD-L1 immunotherapy by negatively regulating proinflammatory chemokines and anticancer immunity. Adv Sci. 2023 Mar;10(8):e2207155. doi:10.1002/advs.202207155.
   Web of Science ®Google Scholar